GlassScriptPhysician profile
Mohammadhamed Labbaf
NPI 1538397310
$27,423.96
in general payments reported to CMS, 2019-2025
71 companies · $5,571 in 2025
The $5,571 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,459 · 2020: $2,506 · 2021: $3,299 · 2022: $3,933 · 2023: $4,601 · 2024: $5,055 · 2025: $5,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $1,185 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,843.03 |
| Consulting Fee | $1,185.00 |
| Education | $198.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,998.73 | 2021-2025 | |
| Lundbeck LLC | $2,367.85 | 2020-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $2,102.75 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,812.71 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Biogen, INC. | $1,812.11 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Lilly USA, LLC | $1,044.41 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Emd Serono, INC. | $989.98 | 2019-2025 | Mavenclad |
| Ucb, INC. | $880.22 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Genentech USA, INC. | $845.24 | 2022-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Pfizer INC. | $748.32 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $737.25 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Eisai INC. | $714.70 | 2022-2025 | |
| Allergan, INC. | $618.86 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $594.09 | 2019-2022 | |
| Amgen INC. | $569.84 | 2019-2025 | Uplizna |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammadhamed Labbaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.